Tevogen Bio Inc: Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q

Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today announced the filing of its quarterly report on Form 10-Q for the quarter ended ...

Precipio, Inc.: Precipio Announces its Q3-2025 Financial Results

Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), filed its 10-Q report today. The following are the highlights of the Company's ...
TheCable

INTERVIEW: ‘Japa’ not a Nigerian thing — humans aren’t designed to stay in one place, says Canada Research Chair

BY ARUKAINO UMUKORO Nigerian-born Canada Research Chair in socially engaged theatre, Professor Taiwo Afolabi, is a globally ...

Exclusive: Ronnie Screwvala’s Upgrad joins list of bidders for bankrupt Byju’s parent

Upgrad has submitted an expression of interest (EoI) to bid for Think & Learn, the bankrupt parent of edtech firm Byju's.

Progyny, Inc. Announces Third Quarter 2025 Results

Selling Season Yields Over 80 New Clients, 900,000 New Lives, and Near 100% Retention of Existing Base Record $156.0 Million in Operating Cash Flow Generated over the First Nine Months of 2025 Board ...

Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell Line

New live-cell imaging data show that Telomir-1 markedly lowers intracellular iron levels at submicromolar concentrations in human keratinocytes, demonstrating potent cell penetration and ...